@FierceBiotech: Penn scientists identify viral products that defend against respiratory syncytial virus. FierceBiotechResearch story | Follow @FierceBiotech
@JohnCFierce: Who you going to buy? Gilead banks $10B, stirring fresh buzz about a blockbuster buyout. Article | Follow @JohnCFierce
@DamianFierce: Flemming Ornskov, "avid postcard and letter writer" who keeps up on household chores. More | Follow @DamianFierce
> Takeda won the FDA's priority review designation for the multiple myeloma treatment ixazomib, guaranteeing a 6-month review time for the drug instead of the usual 10-month process. More
> Third Rock Ventures give Bloomberg a post-mortem on Ember Therapeutics, a once-promising biotech startup whose bet on a new treatment for obesity came up short. Story
> Gene therapy pioneer ReGenXBio updated the terms of its planned IPO, seeking up to $121.4 million to support its pipeline of rare disease treatments. News
Medical Device News
@FierceMedDev: Biogen CEO says the biotech aims to develop wearable and ingestible devices. More | Follow @FierceMedDev
@VarunSaxena2: Robotic surgery aspirant receives $4M+ in equity financing. Story | Follow @VarunSaxena2
@EmilyWFierce: ICYMI from FiercePharma: Roche CEO: Despite China worries, emerging markets will continue to deliver growth. Article | Follow @EmilyWFierce
> JAMA: Women face increased risk for second vaginal mesh surgery 10 years after implant. More
> Delphinus raises $39M+ to back pivotal trial of more effective dense breast tissue ultrasound imaging. Article
Pharma News
@FiercePharma: ICYMI yesterday: Ireland plant with 100 workers on Sun's list for sale or closure. Item | Follow @FiercePharma
@EricPFierce: Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: Icahn casts his eye on Vivus with tender offer for convertible notes. More | Follow @CarlyHFierce
> Study: Patients sticking to their scripts saved Medicaid money. More
> Bernie Sanders unveils bill to battle rising drug prices. Article
Vaccines News
> UC Berkeley scientists identify protein that causes dengue shock as a potential vaccine target. Item
> With limited ACIP nod, U.S. universities take different approaches to Pfizer, GSK MenB jabs. Report
> VBI Vaccines scores up to $265,000 from Canadian organization for RSV vaccine. Story
> Analysis: Sanofi's Fluzone High Dose for adults 65+ results in lower medical costs. Article
> Merck's Zostavax not cost-effective for those in their 50s: Study. More
CRO News
> Aragen licenses a protein technology to speed up biologics R&D. Item
> Rho snags a $120M federal contract with NIH. Story
> Recipharm signs on to make LobSor's Parkinson's drug as it negotiates with Novartis. Article
> Icon teams up with IBM to accelerate clinical trial startup. News
> Surging dollar blunts Catalent's revenue, but profits soar in fiscal '15. Article
Pharma Manufacturing News
> Bangladesh-based Square Pharmaceuticals has two new plants online. Item
> Canada allows Apotex Indian plants to regain access to its markets. More
> GSK recalls more than 425K tubes of antibiotic cream. Report
> Sun targets Ranbaxy plant in Ireland as it prepares to trim manufacturing network. Article
> Glaxo starts $153M plant in India. Story
Pharma Asia News
> Japan's Takeda gets U.S. FDA priority review for ixazomib. Item
> FT counts 39 plants banned in India as regulatory woes mount for drugmakers. More
> China Daily carries lengthy industry-linked op-ed against overuse of stents. Report
> Apotex sees Health Canada lift ban on two India plants. Story
> Chugai and Roche get U.S. FDA priority review on alectinib. Article